ArticleOpen forum infectious diseases2025
Implementation of a Bundle for the Management of Patients With Gram-Negative Bloodstream Infection: A Pre-Post Quasi-experimental Study.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Managing multidrug resistant Gram-negative bacteraemia in immunocompromised hosts.Current opinion in infectious diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lack of international guidelines for gram-negative bloodstream infection (GN-BSI) management poses clinical challenges. We aimed to assess whether implementing a management bundle for patients with GN-BSI affected mortality and/or emergence of multidrug resistance (MDR). Methods: This was a single-center, quasi-experimental study including adult patients hospitalized with monomicrobial GN-BSI. In the preimplementation phase ("pre-phase," 2018-2019), no standardized protocol was used. In the postimplementation phase ("post-phase," 2022-2023), a bundle was applied including predefined rules for follow-up blood cultures (FU-BCs), imaging, β-lactam administration schedule, and treatment duration. Primary endpoint was 30-day all-cause mortality; secondary endpoint was 30-day MDR-GN carriage or infection. Treatment-effect lasso models were used to estimate bundle impact. Results: A total of 2683 patients were included: 1430 in the pre-phase and 1253 in the post-phase. FU-BCs were performed in 22.5% (n = 322) versus 47% (n = 589), Conclusions: The GN-BSI management bundle reduced MDR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.